Multi -party calls on patients to reduce the burden on patients with late gastrointestinal gastrointestinal tumors: "Medical insurance is the biggest relay"

"When I was a prescription four -line drug, I had to look at the patient's expression first. His eyes and expression feedback was important because he might be difficult." This is the chief physician of the Department of Gastrointestinal Medicine of Peking University Cancer Hospital Li Jian. True feelings of patients with interstitial tumors.

July 13th is "Global Gastrointestinal Tumor Getting Love Day". Gastrointestinal tumor is an internationally recognized rare tumor. There are about 20,000 to 30,000 new diagnosis patients every year.

Over the past two decades, the development of targeted drugs has benefited some patients, and many patients have survived for 20 years through medication or even illness. However, in the long -term confrontation with the disease, the problem of drug resistance is gradually prominent. Medical insurance can currently cover the first, second and third -tier medicines, but for the four -line patients, the price of new drugs is prohibitive.

On July 12, a gastrointestinal gastrointestinal tumor care activity entitled "Relay forward and the battery life for life" was held in Beijing. Experts and representatives of the meeting appealed: more secure and effective targeting drugs are included in medical insurance payment.

The life of battery life is urgent

In March 2021, Zaidin Pharmaceutical's Ruicheinib was approved to be listed in China, filling the gap of the four -line treatment of gastrointestinal gastrointestinal tumors. As a standard treatment method for the four -line standard treatment of gastrointestinal gastrointestinal tumors, Ruipitinib has been recommended by the domestic and foreign authoritative diagnosis and treatment guidelines such as the US NCCN and the CSCO of the China Clinical Oncology Society.

Shen Lin, director of the Department of Gastrointestinal Department of Peking University Cancer Hospital, introduced: "The disease of gastrointestinal gastrointestinal tumor is available from no medicine to the emergence of first, second, and third -line therapy drugs. In 20 years, the industry has been continuously studying. Patients have survived for more than 10 years. But we still need more new drugs to treat patients who are already resistant to medicine. "

Patients with late gastrointestinal gastrointestinal tumors cannot be cured, and they can only take targeted drugs. Patients were resistant to medicine after the treatment of first -line, second and third -line targeted drugs, and once faced a situation where there was no medicine.

The Ruicheinib is mainly aimed at this part of patients. However, as we all know, the research and development of new drugs is huge, and the price is generally high. Many patients have given up treatment because of repeated mutations, drug resistance, and economic problems, which makes clinicians very helpless.

The family of a patient with a surname of Wang in Beijing is facing such a dilemma. In 2016, his mother was diagnosed with gastrointestinal tumors and was controlled with surgery and targeted drugs at first. But by September 2021, the condition developed rapidly until the hospital announced the illness in June this year. The doctor believes that taking Ruicheinib still has the opportunity to control the condition, but the cost of tens of thousands of yuan per month makes him a bit unbearable.

The encounter of Rypinib is actually a representative of a class of drugs: it has significant innovation, better treatment effect, but expensive. This type of medicine requires the common aid of enterprises, patients, and insurance.

The Jianzhi Bureau was informed that since the listing, Ruicheini has entered the Huimin Insurance Project in 73 cities. It is the most newly launched innovative drugs in the same period. On July 1, the "Huhui Insurance" guarantee in 2022 was officially effective. More patients have become more patients.

Multi -party relay, medical insurance is the biggest relay

Commercial insurance is only part of the power of multi -party payment. To benefit more patients, medical insurance is the best channel. Liang Yi, chief business officer and president of Greater China, is very clear that besides commercial insurance, the biggest relay is the national medical insurance directory negotiation.

Ruicheinib has been recognized by clinical experts. Ye Yingjiang revealed that the CSCO gastrointestinal tumor diagnosis guide will complete the third edition this year. Because of the small side effects of Ruicheinib, in addition to the fourth -line treatment, it is also used as a second -line treatment for second -line treatment.

It is worth noting that this year's medical insurance negotiations must be completed at least in November. Even if Rypotinib entered the medical insurance smoothly, it may be realized in hospitals in various places. It may be in the first half of next year.

What should I do if the patients who need to take medicine are urgently needed?

The Jianzhi Bureau was informed that the price has been reduced since July of this year, and the cost of purchasing Ruipitinib from hospitals or pharmacies has reduced the cost of 60%. Active price cuts show the sincerity of Ding Ding.

"Patients cannot delay for a minute and one second. We have a sense of urgency." Liang Yi believes that there is the greatest sincerity to help patients with gastrointestinal tumor reduce the burden on the treatment.

In fact, for such innovative drugs, the industry has a relatively mature operating law. Ye Yingjiang, director of the Gastrointestinal Surgery of Peking University People's Hospital, said: "The manufacturer allows a bit of benefits, part of the commercial insurance, and a part of social charity forces. In addition, medical insurance can be included as soon as possible and mobilized all aspects of the power to provide drug support for the survival of these patients. ","

Shen Lin appealed: "I hope that the strength of all parties can bring together and use the difficulties faced by friends of the friends to promote innovative drugs to better benefit patients with advanced gastrointestinal gastrointestinal tumors."

#Innovation Pharmaceutical Company#

- END -